Johnson & Johnson (JNJ) Stock AnalysisJNJJohnson & Johnson

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. Its segments include Innovative Medicine and MedTech. The Innovative Medicine segment focuses on various therapeutic areas, oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular and metabolism. Its products include CARVYKTI (ciltacabtagene autoleucel), DARZALEX (daratumumab), DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), ERLEADA (apalutamide), among others. The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopedics, surgery, and vision supporting physicians, hospitals, eye care professionals and healthcare systems across a range of acute and elective procedures. The Cardiovascular portfolio includes electrophysiology products. It is also focused on proprietary Firelink degrader antibody conjugate platform. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Johnson & Johnson appears to be a good buy right now due to its solid financial performance and positive market sentiment. The current price is $261.44, which is below the average analyst price target of $290, indicating potential upside. Additionally, the company's gross margin stands at 68.33%, reflecting strong profitability. However, there is a risk with insider selling increasing by 159.20% over the last month, which may indicate potential concerns among executives.

23 analysts cover JNJ: 12 rate it Buy, 8 Hold and 3 Sell. The average price target is 218.50.